A Phase 1/2 Study of Combination Osimertinib and Bevacizumab as Treatment for Patients with EGFR-Mutant Lung Cancers
Bevacizumab is an anticancer drug that interferes with the development of the blood vessels that cancers need to grow and spread. It is approved for treating several cancers, including non-small cell lung cancer (NSCLC) when combined with initial chemotherapy.
Patients with NSCLC that contains an EGFR mutation typically receive EGFR inhibitors (such as erlotinib), but the cancer often becomes resistant to those drugs. Osimertinib is a new EGFR inhibitor used to treat NSCLC that has become resistant to other EGFR inhibitors. It is not currently approved to be used as the first EGFR inhibitor for NSCLC.
In this study, researchers want to find the best doses of osimertinib and bevacizumab when these given together in patients with EGFR mutant NSCLC. Osimertinib is taken orally (by mouth), while bevacizumab is given intravenously (by vein).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have EGFR-mutant NSCLC that has not yet been treated with an EGFR inhibitor or a VEGF inhibitor (like bevacizumab).
- At least 2 weeks must pass since completing any prior systemic cancer treatment, 4 weeks since major surgery, and 1 week since radiation therapy and entry into the study.
- This study is for patients age 18 and older.
For more information and to inquire about eligibility for this study, please contact Dr. Helena Yu at 646-888-4274.